X4 Pharmaceuticals, Inc. – NASDAQ:XFOR

Founder-led company

X4 Pharmaceuticals stock price today

$2.98
+2.17
+270.71%
Financial Health
0
1
2
3
4
5
6
7
8
9

X4 Pharmaceuticals stock price monthly change

+14.51%
month

X4 Pharmaceuticals stock price quarterly change

+14.51%
quarter

X4 Pharmaceuticals stock price yearly change

-7.12%
year

X4 Pharmaceuticals key metrics

Market Cap
102.92M
Enterprise value
12.43M
P/E
-0.62
EV/Sales
N/A
EV/EBITDA
-0.13
Price/Sales
N/A
Price/Book
1.29
PEG ratio
-0.01
EPS
-0.98
Revenue
N/A
EBITDA
-114.54M
Income
-165.49M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

X4 Pharmaceuticals stock price history

X4 Pharmaceuticals stock forecast

X4 Pharmaceuticals financial statements

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR): Profit margin
Mar 2023 0 -55.71M
Jun 2023 0 -55.71M
Sep 2023 0 -2.30M
Mar 2024 0 -51.76M
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR): Analyst Estimates
Mar 2024 0 -51.76M
Sep 2025 14.15M -25.83M -182.61%
Oct 2025 7.2M -27.99M -388.87%
Dec 2025 9.13M -24.66M -270.05%
  • Analysts Price target

  • Financials & Ratios estimates

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR): Debt to assets
Mar 2023 173399000 105.86M 61.05%
Jun 2023 173399000 105.86M 61.05%
Sep 2023 173293000 105.69M 60.99%
Mar 2024 112182000 111.14M 99.08%
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR): Cash Flow
Mar 2023 -21.42M -4.88M 69.33M
Jun 2023 -21.42M -4.88M 69.33M
Sep 2023 -20.82M -5.15M 21.20M
Mar 2024 -33.59M -5.32M 0

X4 Pharmaceuticals alternative data

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR): Employee count
Aug 2023 40
Sep 2023 40
Oct 2023 40
Nov 2023 40
Dec 2023 86
Jan 2024 86
Feb 2024 86
Mar 2024 93
Apr 2024 93
May 2024 93
Jun 2024 116
Jul 2024 116

X4 Pharmaceuticals other data

10.95% -61.89%
of XFOR is owned by hedge funds
6.95M -53.65M
shares is hold by hedge funds

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR): Insider trades (number of shares)
Period Buy Sel
Feb 2024 0 53886
Mar 2024 0 131822
Sep 2024 0 2642
Oct 2024 0 657720
Nov 2024 0 31897
Transaction Date Insider Security Shares Price per share Total value Source
Sale
RAGAN PAULA director, officer.. Common Stock 31,897 $0.4 $12,599
Sale
RAGAN PAULA director, officer.. Common Stock 31,897 $0.56 $17,926
Sale
MOSTAFA ADAM S. officer: Chief Fi.. Common Stock 230,645 $0.55 $126,855
Sale
BALDRY MARK officer: Chief Commercial Officer
Common Stock 11,127 $0.59 $6,509
Sale
RAGAN PAULA director, officer.. Common Stock 239,436 $0.55 $131,450
Sale
DIBIASE MARY officer: Chief Operating Officer
Common Stock 67,695 $0.57 $38,315
Sale
TAVERAS ARTHUR officer: Chief Scientific Officer
Common Stock 76,920 $0.56 $43,306
Sale
DIBIASE MARY officer: Chief Operating Officer
Common Stock 2,642 $0.66 $1,738
Sale
TAVERAS ARTHUR officer: Chief Scientific Officer
Common Stock 14,235 $0.88 $12,555
Sale
RAGAN PAULA director, officer.. Common Stock 49,678 $0.88 $43,866
Patent
Application
Filling date: 14 Dec 2021 Issue date: 18 Aug 2022
Grant
Filling date: 10 Apr 2017 Issue date: 24 May 2022
Grant
Filling date: 21 Jun 2017 Issue date: 17 May 2022
Grant
Filling date: 27 Jul 2020 Issue date: 19 Apr 2022
Application
Filling date: 15 Jul 2021 Issue date: 20 Jan 2022
Application
Filling date: 25 Jun 2021 Issue date: 13 Jan 2022
Grant
Filling date: 28 Feb 2020 Issue date: 11 Jan 2022
Application
Filling date: 22 Mar 2021 Issue date: 25 Nov 2021
Application
Filling date: 6 Nov 2018 Issue date: 11 Nov 2021
Grant
Filling date: 5 Dec 2019 Issue date: 29 Jun 2021
Tuesday, 3 December 2024
globenewswire.com
Thursday, 14 November 2024
globenewswire.com
Wednesday, 13 November 2024
seekingalpha.com
globenewswire.com
globenewswire.com
Friday, 1 November 2024
globenewswire.com
Thursday, 24 October 2024
globenewswire.com
Tuesday, 1 October 2024
globenewswire.com
Tuesday, 3 September 2024
globenewswire.com
Wednesday, 28 August 2024
globenewswire.com
Saturday, 10 August 2024
seekingalpha.com
Thursday, 8 August 2024
globenewswire.com
Thursday, 1 August 2024
globenewswire.com
Tuesday, 2 July 2024
seekingalpha.com
Thursday, 27 June 2024
globenewswire.com
Monday, 3 June 2024
globenewswire.com
Wednesday, 29 May 2024
globenewswire.com
Monday, 13 May 2024
globenewswire.com
Thursday, 9 May 2024
globenewswire.com
Tuesday, 7 May 2024
globenewswire.com
Wednesday, 1 May 2024
globenewswire.com
Tuesday, 30 April 2024
GlobeNewsWire
Monday, 29 April 2024
Reuters
Monday, 1 April 2024
GlobeNewsWire
Tuesday, 12 March 2024
GlobeNewsWire
Wednesday, 13 December 2023
Seeking Alpha
Friday, 10 November 2023
GlobeNewsWire
Thursday, 9 November 2023
Seeking Alpha
Thursday, 2 November 2023
GlobeNewsWire
Tuesday, 19 September 2023
GlobeNewsWire
  • What's the price of X4 Pharmaceuticals stock today?

    One share of X4 Pharmaceuticals stock can currently be purchased for approximately $2.98.

  • When is X4 Pharmaceuticals's next earnings date?

    Unfortunately, X4 Pharmaceuticals's (XFOR) next earnings date is currently unknown.

  • Does X4 Pharmaceuticals pay dividends?

    No, X4 Pharmaceuticals does not pay dividends.

  • How much money does X4 Pharmaceuticals make?

    X4 Pharmaceuticals has a market capitalization of 102.92M.

  • What is X4 Pharmaceuticals's stock symbol?

    X4 Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "XFOR".

  • What is X4 Pharmaceuticals's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of X4 Pharmaceuticals?

    Shares of X4 Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are X4 Pharmaceuticals's key executives?

    X4 Pharmaceuticals's management team includes the following people:

    • Dr. Paula Ragan Ph.D. Founder, Chief Executive Officer, Pres, Sec. & Director(age: 55, pay: $551,570)
    • Mr. Derek M. Meisner Esq., J.D. Chief Legal Officer & Corporation Sec.(age: 54, pay: $479,460)
    • Mr. Adam S. Mostafa Chief Financial Officer, Treasurer & Assistant Sec.(age: 45, pay: $400,560)
  • Is X4 Pharmaceuticals founder-led company?

    Yes, X4 Pharmaceuticals is a company led by its founder Dr. Paula Ragan Ph.D..

  • How many employees does X4 Pharmaceuticals have?

    As Jul 2024, X4 Pharmaceuticals employs 116 workers, which is 25% more then previous quarter.

  • When X4 Pharmaceuticals went public?

    X4 Pharmaceuticals, Inc. is publicly traded company for more then 7 years since IPO on 16 Nov 2017.

  • What is X4 Pharmaceuticals's official website?

    The official website for X4 Pharmaceuticals is x4pharma.com.

  • Where are X4 Pharmaceuticals's headquarters?

    X4 Pharmaceuticals is headquartered at 61 North Beacon Street, Boston, MA.

  • How can i contact X4 Pharmaceuticals?

    X4 Pharmaceuticals's mailing address is 61 North Beacon Street, Boston, MA and company can be reached via phone at 857 529 8300.

X4 Pharmaceuticals company profile:

X4 Pharmaceuticals, Inc.

x4pharma.com
Exchange:

NASDAQ

Full time employees:

127

Industry:

Biotechnology

Sector:

Healthcare

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.

61 North Beacon Street
Boston, MA 02134

CIK: 0001501697
ISIN: US98420X1037
CUSIP: 98420X103